Advertisement

Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies

  • Daisuke Minakata
  • Shin-ichiro Fujiwara
  • Takashi Ikeda
  • Shin-ichiro Kawaguchi
  • Yumiko Toda
  • Shoko Ito
  • Shin-ichi Ochi
  • Takashi Nagayama
  • Kiyomi Mashima
  • Kento Umino
  • Hirofumi Nakano
  • Ryoko Yamasaki
  • Kaoru Morita
  • Yasufumi Kawasaki
  • Miyuki Sugimoto
  • Chihiro Yamamoto
  • Masahiro Ashizawa
  • Kaoru Hatano
  • Kazuya Sato
  • Iekuni Oh
  • Ken Ohmine
  • Kazuo Muroi
  • Tsukasa Ohmori
  • Yoshinobu Kanda
Original Article
  • 38 Downloads

Abstract

We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT). We retrospectively examined 127 patients [acute myeloid leukemia (n = 48), acute lymphoblastic leukemia (n = 25), and non-Hodgkin lymphoma (n = 54)] with DIC, who were diagnosed according to Japanese Ministry of Health, Labour and Welfare criteria and treated with SPIs [FOY (n = 55) and FUT (n = 72)] at our hospital from 2006 to 2015. The DIC resolution rates on days 7 and 14 were 42.6% and 62.4%, respectively. No significant differences were observed in DIC resolution rates between the FUT and FOY groups [40.3% vs. 45.5% (day 7), P = 0.586; 56.3% vs. 69.8% (day 14), P = 0.179, respectively]. Multivariate analysis revealed that response to chemotherapy was the only independent predictor of DIC resolution on days 7 and 14 (ORR 2.81, 95% CI 1.32–5.98, P = 0.007; ORR 2.51, 95% CI 1.12–5.65, P = 0.026). Resolution of DIC was correlated with improvement of background hematological malignancies, and no significant differences were observed between the two SPIs.

Keywords

Disseminated intravascular coagulation Gabexate mesilate Nafamostat mesilate Synthetic protease inhibitors Hematological malignancy 

Notes

Author contributions

DM collected data and wrote the manuscript; SF collected data and wrote the manuscript; YK and TO designed this report, interpreted the results and wrote the manuscript; YS, TI, SK, YT, SI, SO, TN, KM, KU, HN, RY, KM, YK, MS, CY, MA, KH, KS, IO, KO, KM, reviewed the manuscript, contributed to the interpretation of the data, and approved the final version.

Compliance with ethical standards

Conflict of interest

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. We declare that we have no conflicts of interest.

References

  1. 1.
    Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016;14:42.CrossRefGoogle Scholar
  2. 2.
    Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125:6–11.CrossRefGoogle Scholar
  3. 3.
    Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–92.CrossRefGoogle Scholar
  4. 4.
    Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010;38(2 Suppl):35–42.CrossRefGoogle Scholar
  5. 5.
    Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103:253–61.CrossRefGoogle Scholar
  6. 6.
    Ohno H, Kosaki G, Kambayashi J, Imaoka S, Hirata F. FOY: [ethyl P-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res. 1980;19:579–88.CrossRefGoogle Scholar
  7. 7.
    Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis. 1985;15:164–8.Google Scholar
  8. 8.
    Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol. 1983;49:265–75.Google Scholar
  9. 9.
    Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.CrossRefGoogle Scholar
  10. 10.
    Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:20.CrossRefGoogle Scholar
  11. 11.
    Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.CrossRefGoogle Scholar
  12. 12.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefGoogle Scholar
  13. 13.
    Ino Y, Suzuki K, Sato T, Iwaki M. Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro. Folia Pharmacol Jpn. 1986;88:449–55.CrossRefGoogle Scholar
  14. 14.
    Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41:155–62.CrossRefGoogle Scholar
  15. 15.
    Shibata S, Takahashi H, Aoki N, Takahashi H, Aoki N, Matsuda T, et al. Evaluation of clinical effect of FUT-175 on DIC: multi-center clinical comparative study. Rinsho Kenkyu. 1988;65:921–40.Google Scholar
  16. 16.
    Kosaki G, Kambayashi J, Hirabayashi A, Mori K, Uchida T, Abe T, et al. Evaluation of clinical effect of FOY on DIC: multi-center clinical comparative study. Igaku no Ayumi. 1983;124:144–54.Google Scholar

Copyright information

© Japanese Society of Hematology 2018

Authors and Affiliations

  • Daisuke Minakata
    • 1
  • Shin-ichiro Fujiwara
    • 1
  • Takashi Ikeda
    • 1
  • Shin-ichiro Kawaguchi
    • 1
  • Yumiko Toda
    • 1
  • Shoko Ito
    • 1
  • Shin-ichi Ochi
    • 1
  • Takashi Nagayama
    • 1
  • Kiyomi Mashima
    • 1
  • Kento Umino
    • 1
  • Hirofumi Nakano
    • 1
  • Ryoko Yamasaki
    • 1
  • Kaoru Morita
    • 1
  • Yasufumi Kawasaki
    • 1
  • Miyuki Sugimoto
    • 1
  • Chihiro Yamamoto
    • 1
  • Masahiro Ashizawa
    • 1
  • Kaoru Hatano
    • 1
  • Kazuya Sato
    • 1
  • Iekuni Oh
    • 1
  • Ken Ohmine
    • 1
  • Kazuo Muroi
    • 1
  • Tsukasa Ohmori
    • 2
  • Yoshinobu Kanda
    • 1
  1. 1.Division of Hematology, Department of MedicineJichi Medical UniversityShimotsukeJapan
  2. 2.Department of BiochemistryJichi Medical UniversityShimotsukeJapan

Personalised recommendations